Study of a new phosphate binder for dialysis patients
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called AP301 to lower high phosphate levels in people on dialysis. It's designed to help control phosphate, which can be hard to manage with diet and current medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old.
- You must have been on dialysis for at least 3 months.
- Your dialysis must be working well enough (measured by a standard test).
- If you are on current phosphate-lowering drugs, your phosphate level must be within a certain range before and after a washout period.
- You cannot have had or be planning a kidney transplant.
- You cannot have had recent parathyroid surgery or have severe calcium or parathyroid hormone problems.
- You cannot have a serious stomach or bowel condition, or have had certain stomach surgeries in the last 3 months.
- You must not be allergic to any ingredient in AP301 or have a history of severe allergies.
- You cannot be breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called AP306 for people on hemodialysis who have high blood phosphate. It aims to see if the drug is safe, tolerable, and helps lower phosphate levels.
This trial compares two treatment goals for blood phosphate levels in people with end-stage kidney disease who are on dialysis. It may help determine which target is safer and works better in real-world care.
This trial tests a new drug, JMKX003002, to lower high phosphorus levels in people with end-stage kidney disease who are on hemodialysis. If you have trouble controlling your phosphorus, this treatment might help.
This trial tests a new medicine called TS-172 for people with high phosphorus levels who are on hemodialysis. It aims to lower phosphorus levels and is taken along with your current phosphate binder medication.
This study tests whether a new medicine called TS-172 can help lower phosphorus levels in patients on peritoneal dialysis (a type of kidney treatment). High phosphorus can cause bone problems and other complications, so the trial aims to see if this drug works better than current treatments.
This study tests a new medicine called AP303 for people with type 2 diabetes and chronic kidney disease. The goal is to see if it is safe and how the body processes it. If you have diabetes and your kidneys are not working as well as they used to, this trial might help find new treatment options.
Hear when a new Hyperphosphatemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.